Watchlist Price Alert

Y-mAbs Therapeutics Inc. (YMAB)

NASDAQ: YMAB · Real-Time Price · USD

3.87

0.23 (6.32%)

At close: May 15, 2025, 3:59 PM

6.32% (1D)

Bid	3
Market Cap	175.02M
Revenue (ttm)	88.66M
Net Income (ttm)	-28.23M
EPS (ttm)	-0.67
PE Ratio (ttm)	-5.77
Forward PE	-3.86
Analyst	Buy

Ask	4.17
Volume	131,004
Avg. Volume (20D)	308,386
Open	3.57
Previous Close	3.64
Day's Range	3.57 - 3.88
52-Week Range	3.55 - 16.11
Beta	0.52

About YMAB

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol YMAB

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for YMAB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Y-mAbs Therapeutics has released their quartely earnings on May 13, 2025:

Revenue of $20.9M exceeds estimates by $1.29M, with 4.88% YoY growth.

EPS of -0.12 exceeds estimates by 0.08, with 20.00% YoY growth.

Why Price Moved

5 months ago

-0.77%

Y-MAbs Therapeutics shares are trading higher afte... Unlock content with Pro Subscription

9 months ago

+10.63%

Y-mAbs Therapeutics shares are trading. The stock may be rebounding after falling earlier in the week on weak earnings and guidance.

News

3 days ago · seekingalpha.com

Y-mAbs Therapeutics, Inc. (YMAB) Q1 2025 Earnings Call Transcript

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Courtney Dugan - Vice President, Head of Investor Relations Michael Rossi - Presi...

2 days ago · zacks.com

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates

Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.15 per share a year ago.

2 weeks ago · zacks.com

Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q1 Earnings Expected to Decline

YmAbs Therapeutics (YMAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago · seekingalpha.com

Y-mAbs Therapeutics: A Yawn From The Market Means Opportunity

YMAB's naxitamab shows a 50% overall response rate in phase 2 trials for high-risk neuroblastoma, supporting its ongoing commercialization efforts. The SADA platform, targeting GD2 and CD38, is YMAB's...

2 months ago · seekingalpha.com

Y-mAbs Therapeutics, Inc. (YMAB) Q4 2024 Earnings Call Transcript

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB ) Q4 2024 Earnings Conference Call March 4, 2025 8:00 AM ET Company Participants Courtney Dugan - Head-IR Michael Rossi - President & CEO Doug Gentilcore - Senio...

2 months ago · zacks.com

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Lags Revenue Estimates

Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.02 per share a year ago.

2 months ago · zacks.com

Y-mAbs Therapeutics, Inc. (YMAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

YmAbs Therapeutics (YMAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.